

I. AMENDMENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or a pharmaceutically acceptable salt thereof in a range of 500 to 4900 mg/m² and administering an effective amount of gemcitabine wherein the DMXAA or the pharmaceutically acceptable salt thereof and the gemcitabine are administered in a potentiating ratio.
2. (currently amended) ~~[[A]] The method according to claim 1 for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt thereof and administering an effective amount of gemcitabine in a~~ wherein the potentiating ratio is in a range of 1:100 to 1:2.
3. (currently amended) The method according to claim 1 ~~or claim 2~~, wherein the DMXAA or pharmaceutically acceptable salt thereof and gemcitabine are administered concomitantly.
4. (Previously Presented) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt thereof and administering an effective amount of gemcitabine, wherein the DMXAA or pharmaceutically acceptable salt thereof and the gemcitabine are administered sequentially.
- 5-6. (Cancelled).
7. (currently amended) A pharmaceutical dosage for treating a solid cancerous tumor comprising ~~an effective amount of DMXAA or a pharmaceutically acceptable salt thereof in an amount to provide a dosage in a range of 500 to 4900 mg/m² and an effective amount of~~ gemcitabine in a potentiating ratio in a mammal ~~for treating a solid cancerous tumor.~~

8-10. (Cancelled).

11. (currently amended) A pharmaceutical formulation comprising a potentiating ratio of combination of DMXAA or a pharmaceutically acceptable salt thereof and gemcitabine in association with one or more pharmaceutically acceptable carriers therefor.

12. (Previously Presented) The pharmaceutical formulation according to claim 11 wherein the formulation is adapted for intravenous administration.

13-15. (Cancelled).

16. (currently amended) A process for the preparation of a pharmaceutical formulation which process comprises bringing into association a potentiating ratio of combination of DMXAA or a pharmaceutically acceptable salt thereof and gemcitabine with one or more pharmaceutically acceptable carriers therefor.

17-19. (Cancelled).

20. (currently amended) A kit comprising in association for separate administration a potentiating ratio of DMXAA or a pharmaceutically acceptable salt thereof and gemcitabine.

21-27. (Cancelled).

28. (New) The method according to claim 1, wherein the solid cancerous tumor is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, breast cancer, pancreatic cancer, ovarian cancer, colorectal cancer, prostate cancer, gastric cancer, testicular cancer, bladder cancer, colonic carcinoma, parvocellular bronchial carcinoma, non-parvocellular bronchial carcinoma, cephalic carcinoma, cervical carcinoma, thoracic carcinoma, abdominal carcinoma, endometrial carcinoma, sarcoma, melanoma, and leukemia.